- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
Search Results
240 results for
SAXPY Stock Earnings: Sampo Reported Results for Q1 2024
Sampo just reported results for the first quarter of 2024.
AHEXY Stock Earnings: Adecco Group Reported Results for Q1 2024
Adecco Group just reported results for the first quarter of 2024.
SNCY Stock Earnings: Sun Country Airlines Misses EPS, Misses Revenue for Q1 2024
SNCY stock results show that Sun Country Airlines missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q1 2024
IDYA stock results show that IDEAYA Biosciences missed analyst estimates for earnings per share the first quarter of 2024.
EVEX Stock Earnings: Eve Holding Beats EPS for Q1 2024
EVEX stock results show that Eve Holding beat analyst estimates for earnings per share the first quarter of 2024.
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
SEAT Stock Earnings: Vivid Seats Misses EPS, Beats Revenue for Q1 2024
SEAT stock results show that Vivid Seats missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024
ARVN stock results show that Arvinas beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024
ZNTL stock results show that Zentalis Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
CLPBY Stock Earnings: Coloplast Reported Results for Q2 2024
Coloplast just reported results for the second quarter of 2024.
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024
NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the first quarter of 2024.
FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024
FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
TOVX Stock Earnings: Theriva Biologics Beats EPS for Q1 2024
TOVX stock results show that Theriva Biologics beat analyst estimates for earnings per share the first quarter of 2024.
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024
SRRK stock results show that Scholar Rock Holding missed analyst estimates for earnings per share the first quarter of 2024.
PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024
PRLD stock results show that Prelude Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
OFIX Stock Earnings: Orthofix Medical Meets EPS, Beats Revenue for Q1 2024
OFIX stock results show that Orthofix Medical met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
QURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024
QURE stock results show that uniQure missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024
CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
RPHM Stock Earnings: Reneo Pharmaceuticals Beats EPS for Q1 2024
RPHM stock results show that Reneo Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024
MLTX stock results show that MoonLake missed analyst estimates for earnings per share the first quarter of 2024.
NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024
NVCT stock results show that Nuvectis Pharma beat analyst estimates for earnings per share the first quarter of 2024.
2 – 10 of 240 results
